Kerri Fitzgerald

DocwireNews

In a case study published in Blood Advances, researchers detail the account of a patient with multiple myeloma (MM) and <a href="https://www.docwirenews.com/home-page-editor-picks/the-covid-19-pandemic-global-cases-now-exceed-1-million-dr-fauci-explains-why-social-distancing-wont-prevent-peak-and-more/">COVID-19</a> who was treated with the immunosuppressant tocilizumab and demonstrated gradual recovery, which the researchers said indicates &ldquo;that tocilizumab is effective in the treatment of novel coronavirus infection.&rdquo;The patient was a 60-year-old man who was diagnosed with MM in 2015 and was receiving maintenance therapy. He worked in <a href="https://www.docwirenews.com/home-page-editor-picks/everything-you-need-to-know-about-the-wuhan-coronavirus-outbreak-2/">Wuhan, China</a>, and was hospitalized in February 2020 for chest tightness and shortness of breath and subsequently tested positive for COVID-19, despite the absence of cough and fever, which are typical symptoms associated with a positive diagnosis.Chest computed tomography (CT) scan showed multiple ground-glass opacities in the man&rsquo;s lungs&mdash;characteristic of pneumonia. He also had high levels of interleukin (IL) 6.<h2>Patient outcomes after tocilizumab treatment</h2>The man was treated with antiviral and corticosteroid therapies, including moxifloxacin 400 mg intravenously (IV) daily for three days and umifenovir 200 mg orally three times per day. He received methylprednisone 40 mg IV daily on days two through six, after which his breathing had improved but his chest tightness remained. On day nine, the patient received a single dose of tocilizumab 8 mg/kg IV.Tocilizumab is approved to treat cytokine release syndrome related to chimeric antigen receptor T-cell therapy.His IL-6 levels declined gradually after tocilizumab administration over the next 10 days, from 121.59 pg/mL to 20.81 pg/mL. They then increased rapidly to 317.38 pg/mL and declined again to 117.1 pg/mL.The man&rsquo;s chest tightness resolved on day 12; by day 19, a chest CT showed decline in the range of ground-glass opacities, and he was declared &ldquo;cured&rdquo; and discharged from the hospital. He had no MM symptoms at this time.&ldquo;Our patients with hematologic malignancies are immunosuppressed, which may put them at higher risk for novel coronavirus infection. What are the characteristics of COVID-19 in patients with blood cancers? What is the optimal treatment approach? Everything is unknown, and that was the motivation for this study,&rdquo; said lead study author Changcheng Zheng, MD, of the University of Science and Technology of China, in a press release.He also indicated that since the patient had chest tightness and shortage of breath without cough and fever, clinical symptoms of coronavirus may not follow the typical symptom pattern in patients with hematologic malignancies.The U.S. Food and Drug Administration has since approved a randomized, double-blind, placebo-controlled, phase III trial to assess the safety and efficacy of&nbsp;IV tocilizumab to treat COVID-19.

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Tocilizumab May be a Treatment Option for Patients with Hematologic Malignancies and COVID-19

COVID-19

In a case study published in Blood Advances, researchers detail the account of a patient with multiple myeloma (MM) and COVID-19 who was treated with the immunosuppressant ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe